source
- Scholar Rock receives FDA approval for apitegromab (Isembyld) to treat spinal muscular atrophyScholar Rock announced FDA approval for its injectable drug apitegromab, marketed as Isembyld, for treating spinal muscular atrophy, a rare muscle-wasting condition. The approval follows earlier s…
- GSK reports 94% response rate for Jideytro in ROS1-positive lung cancer at World ConferenceGSK is moving a newly acquired lung-cancer drug, Jideytro, toward FDA review after presenting data at the World Conference on Lung Cancer. The conference data showed a 94% response rate when Jidey…